Mark A Rubin

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays
    Francesca Demichelis
    Bionformatics, SRA, ITC irst and Dept of Information and Communication Technology, University of Trento, Trento, Italy
    BMC Bioinformatics 7:514. 2006
  2. ncbi Using molecular markers to predict outcome
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 172:S18-21; discussion S21-2. 2004
  3. ncbi Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Am J Surg Pathol 28:946-52. 2004
  4. ncbi Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 64:3814-22. 2004
  5. pmc Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, and the Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 164:831-40. 2004
  6. ncbi Effect of finasteride on risk of prostate cancer: how little we really know
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Cell Biochem 91:478-82. 2004
  7. ncbi Molecular genetics of human prostate cancer
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 17:380-8. 2004
  8. ncbi Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death
    Mark A Rubin
    Department of Pathology Amory 3 195, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1424-32. 2005
  9. pmc Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer
    Rohit Mehra
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Res 68:3584-90. 2008
  10. pmc Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer
    Bharathi Laxman
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 8:885-8. 2006

Collaborators

Detail Information

Publications99

  1. pmc A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays
    Francesca Demichelis
    Bionformatics, SRA, ITC irst and Dept of Information and Communication Technology, University of Trento, Trento, Italy
    BMC Bioinformatics 7:514. 2006
    ..The aim of this paper is to provide and validate a classification model taking into consideration the uncertainty associated with measuring replicate samples...
  2. ncbi Using molecular markers to predict outcome
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 172:S18-21; discussion S21-2. 2004
    ..Developing molecular tests to predict prostate cancer progression requires first defining meaningful clinical end points and defining strategies to take advantage of emerging technology...
  3. ncbi Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Am J Surg Pathol 28:946-52. 2004
    ..Knowledge of how pathology biopsy reports are being used should help evaluate what data should be uniformly part of standard biopsy pathology report and help improve communication between pathologists and urologists...
  4. ncbi Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 64:3814-22. 2004
    ..In summary, these findings suggest that dysregulation of TPD52 by genomic amplification and androgen induction may play a role in prostate cancer progression...
  5. pmc Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, and the Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 164:831-40. 2004
    ..In the future, the AMACR AQUA Z-score may be useful in the automated screening and evaluation of prostate tissue biomarkers...
  6. ncbi Effect of finasteride on risk of prostate cancer: how little we really know
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Cell Biochem 91:478-82. 2004
    ..Confirmation of a spurious tumor grade "inflation" will make the conclusions of this study clearer and define the benefits of finasteride chemoprevention in a more favorable light...
  7. ncbi Molecular genetics of human prostate cancer
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 17:380-8. 2004
    ..Molecular studies have also identified genes that are frequently altered in sporadic prostate cancer. It appears that due to the heterogeneity of prostate cancer, multiple genes may be involved in the neoplastic process...
  8. ncbi Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death
    Mark A Rubin
    Department of Pathology Amory 3 195, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1424-32. 2005
    ..This is the first study to show that AMACR expression is significantly associated with prostate cancer progression and suggests that not all surrogate end points may be optimal to define biomarkers of aggressive prostate cancer...
  9. pmc Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer
    Rohit Mehra
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Res 68:3584-90. 2008
    ..These findings suggest that TMPRSS2-ERG with Edel is an aggressive and, in this study, uniformly lethal molecular subtype of prostate cancer associated with androgen-independent disease...
  10. pmc Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer
    Bharathi Laxman
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 8:885-8. 2006
    ..These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer...
  11. pmc Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Cancer Inst 100:815-25. 2008
    ....
  12. pmc Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer
    Sooryanarayana Varambally
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 10:1285-94. 2008
    ..0009) versus 0.495 for serum PSA (P = .902). Our data indicating the up-regulation of GOLM1 expression and its appearance in patients' urine suggest GOLM1 as a potential novel biomarker for clinically localized prostate cancer...
  13. pmc Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort
    Lorelei A Mucci
    Channing Laboratory, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:1682-8. 2008
    ..78) than the clinical model alone (area under the curve = 0.71; P = 0.04). Molecular tumor markers can add to clinical variables to help distinguish lethal and indolent prostate cancer and hold promise to guide treatment decisions...
  14. pmc Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States
    Juan Miguel Mosquera
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:4706-11. 2009
    ..We sought to determine the prevalence of TMPRSS2-ERG gene fusion among prostate-specific antigen-screened men undergoing prostate biopsy in the United States...
  15. ncbi Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602, USA
    Science 310:644-8. 2005
    ..These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer...
  16. pmc Characterizing the cancer genome in lung adenocarcinoma
    Barbara A Weir
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 450:893-8. 2007
    ..More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered...
  17. pmc Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease
    Dolores Di Vizio
    The Urological Diseases Research Center, Children s Hospital Boston, Boston, MA 02115, USA
    Cancer Res 69:5601-9. 2009
    ..They also show that DRF3 is a physiologically relevant protein that seems to regulate this process...
  18. ncbi Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations
    Rajal B Shah
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor 48109, USA
    Am J Clin Pathol 122:517-23. 2004
    ..The cocktail provides a simple, cost-effective improvement in basal cell immunohistochemical analysis of difficult prostate lesions...
  19. ncbi Integrative analysis of genomic aberrations associated with prostate cancer progression
    Jung H Kim
    Michigan Center for Translational Pathology, Department of Pathology, Department of Urology, Program of Bioinformatics, and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109 0940, USA
    Cancer Res 67:8229-39. 2007
    ..Integrative analysis with matched mRNA profiles identified genetic alterations in several proposed candidate genes implicated in prostate cancer progression...
  20. ncbi Prognostic factors in lymph node-positive prostate cancer
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Urology 67:1016-21. 2006
    ..The incidence of clinically localized PCa with concurrent lymph node metastasis has decreased to less than 1% in the United States but is between 10% and 15% in other countries...
  21. pmc An oncogenic role for ETV1 in melanoma
    Judit Jane-Valbuena
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 70:2075-84. 2010
    ..These observations implicate deregulated ETV1 in melanoma genesis and suggest a pivotal lineage dependency mediated by oncogenic ETS transcription factors in this malignancy...
  22. pmc Role of the TMPRSS2-ERG gene fusion in prostate cancer
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 10:177-88. 2008
    ..Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer...
  23. ncbi Integrative molecular concept modeling of prostate cancer progression
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nat Genet 39:41-51. 2007
    ..Taken together, these data show that analyzing gene expression signatures in the context of a compendium of molecular concepts is useful in understanding cancer biology...
  24. ncbi Autoantibody signatures in prostate cancer
    Xiaoju Wang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    N Engl J Med 353:1224-35. 2005
    ..New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer...
  25. pmc Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model
    Kirsten D Mertz
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115 6110, USA
    Neoplasia 9:200-6. 2007
    ..The androgen receptor-negative NCI-H660 cell line expresses ERG in an androgen-independent fashion. This in vitro model system has the potential to provide important pathobiologic insights into TMPRSS2-ERG fusion prostate cancer...
  26. pmc α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study
    Marc Barry
    Department of Pathology, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Prostate 72:301-6. 2012
    ..Recent studies suggest that low AMACR expression is associated with biochemical recurrence and the development of fatal disease...
  27. ncbi Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 448:595-9. 2007
    ..Furthermore, the identification of androgen-repressed and insensitive 5' fusion partners may have implications for the anti-androgen treatment of advanced prostate cancer...
  28. ncbi The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  29. ncbi Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer
    Daniel R Rhodes
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    J Natl Cancer Inst 95:661-8. 2003
    ....
  30. pmc Defining aggressive prostate cancer using a 12-gene model
    Tarek A Bismar
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Neoplasia 8:59-68. 2006
    ..0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process...
  31. pmc Internet-based Profiler system as integrative framework to support translational research
    Robert Kim
    Department of Pathology, Brigham and Women s Hospital, Boston, USA
    BMC Bioinformatics 6:304. 2005
    ..The Profiler system allows investigator to reliably track, store, and evaluate TMA experiments. Here within we describe the process that has evolved through an empirical basis over the past 5 years at two academic institutions...
  32. doi Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer
    Kirsten D Mertz
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Int J Cancer 123:569-76. 2008
    ..Distinct molecular subtypes of ccRCC with prognostic relevance were identified, and the CK7/CK19 expressing subtype is associated with better outcome...
  33. ncbi Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
    Sven Perner
    Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:696-701. 2007
    ..6-9.7, P < .001, respectively). In summary, PSMA is independently associated with PSA recurrence in a high-risk cohort and thus might provide insight into the additional use of adjuvant therapy. Validation on other cohorts is required...
  34. pmc Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer
    Simpa S Salami
    Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Urol Oncol 31:566-71. 2013
    ..We sought to develop a clinical algorithm combining serum PSA with detection of TMPRSS2:ERG fusion and PCA3 in urine collected after digital rectal exam (post-DRE urine) to predict prostate cancer on subsequent biopsy...
  35. ncbi Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Cell 8:393-406. 2005
    ....
  36. ncbi TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion
    Sven Perner
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115 6110, USA
    Am J Surg Pathol 31:882-8. 2007
    ..Furthermore, its clinical application as a biomarker and ancillary diagnostic test is promising given its high specificity...
  37. pmc Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications
    Juan Miguel Mosquera
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Clin Cancer Res 14:3380-5. 2008
    ..This may have significant clinical implications given that TMPRSS2-ERG fusion prostate cancer is associated with a more aggressive clinical course...
  38. ncbi Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer
    Arun Sreekumar
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    J Natl Cancer Inst 96:834-43. 2004
    ..However, attempts to detect AMACR in circulation have not been successful. Hence, we determined whether an immune response to AMACR could be used as a serum biomarker for prostate cancer...
  39. pmc Aberrant cytoplasmic expression of p63 and prostate cancer mortality
    Preet K Dhillon
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:595-600. 2009
    ..The mislocalized expression was associated with reduced apoptosis and higher proliferative activity and may suggest an oncogenic role in prostate cancer progression and survival...
  40. doi Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, 2Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 69:640-6. 2009
    ....
  41. ncbi Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer
    Rohit Mehra
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Mod Pathol 20:538-44. 2007
    ....
  42. ncbi Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arch Pathol Lab Med 130:989-96. 2006
    ..The metastasis-associated gene 1 (MTA1) is overexpressed in several human cancers. Recent reports suggest that MTA1 may play a role in cancer progression either through transcription repression and/or hormone receptor interactions...
  43. ncbi TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
    Sven Perner
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115 6110, USA
    Cancer Res 66:8337-41. 2006
    ..The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement...
  44. ncbi alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    JAMA 287:1662-70. 2002
    ..Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens...
  45. ncbi Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115 6110, USA
    Lab Invest 86:1099-102. 2006
    ..The clinical implications of this discovery are significant for diagnosis and potentially for the development of targeted therapy...
  46. doi Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 19:229-39. 2010
    ..Given PCA's strong genetic component, we evaluated the possibility that variation in genes involved in DHT metabolism influence PCA risk...
  47. ncbi Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase
    Dolores Di Vizio
    The Urological Diseases Research Center and Department of Surgery, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell Cycle 7:2257-67. 2008
    ..These findings suggest that FASN and Cav-1 physically and functionally interact in PCa cells. They also imply that palmitoylation within this complex is involved in tumor growth and survival...
  48. ncbi Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis
    Agnieszka K Witkiewicz
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 14:1418-23. 2005
    ..Quantitative image analysis is a novel way to accurately and reproducibly evaluate immunohistochemistry in breast tissue samples using high-density tissue microarrays...
  49. ncbi Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
    Levi A Garraway
    Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 436:117-22. 2005
    ..Together, these data suggest that MITF represents a distinct class of 'lineage survival' or 'lineage addiction' oncogenes required for both tissue-specific cancer development and tumour progression...
  50. pmc Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney
    Rameen Beroukhim
    Departments of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 69:4674-81. 2009
    ....
  51. pmc Whole transcriptome amplification for gene expression profiling and development of molecular archives
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    Neoplasia 8:153-62. 2006
    ..Taken together, WTA represents a versatile approach to profile and archive cDNA from minute tumor samples and is compatible with partially degraded RNA...
  52. ncbi TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109, USA
    Cancer Res 66:3396-400. 2006
    ..This result defines a third molecular subtype of prostate cancer and supports the hypothesis that dysregulation of ETS family members through fusions with TMRPSS2 may be an initiating event in prostate cancer development...
  53. pmc Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer
    Chandan Kumar-Sinha
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0602, USA
    Am J Pathol 164:787-93. 2004
    ..Taken together, our studies suggest that AMACR activity is increased in prostate cancer relative to benign epithelia and suggests that monitoring AMACR activity levels in prostate needle biopsies may have clinical applications...
  54. pmc mRNA expression signature of Gleason grade predicts lethal prostate cancer
    Kathryn L Penney
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 29:2391-6. 2011
    ....
  55. pmc Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation
    Nishit K Mukhopadhyay
    Urological Diseases Research Center, Department of Urology, Children s Hospital Boston, Boston, MA 02115, USA
    Cancer Res 69:2210-8. 2009
    ..HnRNP-K is the first protein identified that directly interacts with and regulates the AR translational apparatus...
  56. ncbi Identification of two molecular groups of seminomas by using expression and tissue microarrays
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 11:5722-9. 2005
    ..One group of seminomas has a molecular profile similar to embryonal carcinoma. The findings in the current study may help explain aberrant immunoprofiles seen with some seminomas...
  57. ncbi The role of metastasis-associated protein 1 in prostate cancer progression
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 64:825-9. 2004
    ..In summary, this study identified an association of MTA1 expression and prostate cancer progression...
  58. pmc Amplification of chromosomal segment 4q12 in non-small cell lung cancer
    Alex H Ramos
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA, USA
    Cancer Biol Ther 8:2042-50. 2009
    ..Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors...
  59. pmc Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays
    Rameen Beroukhim
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    PLoS Comput Biol 2:e41. 2006
    ..We have developed a method for analyzing high-density oligonucleotide SNP array data to accurately identify of regions of LOH and retention in tumors without the need for paired normal samples...
  60. ncbi Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
    Rajal B Shah
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Cancer Res 64:9209-16. 2004
    ..An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease...
  61. pmc Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma
    Justine A Barletta
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Cell Mol Med 13:1977-86. 2009
    ..Patients with no TTF-1 expression or TTF-1 expression and TTF-1 gene amplification tend to have a significantly worse prognosis than patients with TTF-1 expression and no TTF-1 gene amplification...
  62. ncbi Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 67:10296-303. 2007
    ..Our results indicate that this pathway is especially dysregulated in hormone-refractory prostate cancer...
  63. pmc Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neoplasia 6:503-12. 2004
    ..2-fold downregulation). Taken together, this study suggests that only a small subset of PCas may be amenable to tyrosine kinase inhibitors specific for PDGFR...
  64. doi Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer
    Mohamed S Arredouani
    Division of Urology, Department of Surgery, Genomics Center, and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 15:5794-802. 2009
    ..We sought to identify novel PCa tumor-associated antigens (TAA) that are expressed in PCa, absent in nonprostate human tissue, and immunogenic for immune responses restricted by human HLA. Experimental Design and..
  65. ncbi Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases
    Jacqueline Banyard
    Vascular Biology Program, Department of Surgery, Children s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 13:2634-42. 2007
    ..The purpose of this study was to determine the expression of collagen XXIII in human prostate cancer and investigate its relationship with disease progression...
  66. ncbi JAGGED1 expression is associated with prostate cancer metastasis and recurrence
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 64:6854-7. 2004
    ....
  67. pmc alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation
    Rainer Kuefer
    Department of Pathology, University of Michigan Medical School, Ann Arbor 48109 0602, USA
    Am J Pathol 161:841-8. 2002
    ..Taken together, these data suggest that AMACR expression is not hormone-dependent but may in fact be a marker of tumor differentiation...
  68. ncbi Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens
    Tara Jane Browne
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 35:1462-8. 2004
    ..However, a limitation of this approach is the loss of tissue in these small lesions, suggesting that combining AMACR and the BCC on a single slide would be superior to using either marker separately...
  69. ncbi Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions
    Ming Zhou
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, USA
    Am J Surg Pathol 26:926-31. 2002
    ..In conclusion, our study suggests that AMACR is potentially an important tumor marker for several cancers and their precursor lesions, especially those linked to high-fat diets...
  70. doi Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort
    Lorelei A Mucci
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:249-51. 2008
    ..We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer...
  71. ncbi Integrative biology of prostate cancer progression
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Annu Rev Pathol 1:243-71. 2006
    ..This review addresses candidate genes involved in prostate cancer pathogenesis in a biological and clinical context and demonstrates how integrated analysis of high-throughput data augments our understanding of prostate cancer...
  72. pmc Detection of early prostate cancer using a hepsin-targeted imaging agent
    Kimberly A Kelly
    Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Cancer Res 68:2286-91. 2008
    ..HPN imaging may provide a new method for detection of prostate cancer...
  73. ncbi Tech.Sight. Understanding disease cell by cell
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Science 296:1329-30. 2002
  74. doi Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 22:933-9. 2009
    ..This may suggest a potential role for metastasis-associated gene 1 in the malignant progression and metastasis and its use as biomarker for malignant pancreatic endocrine tumors...
  75. ncbi Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer
    Daniel R Rhodes
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 62:4427-33. 2002
    ..Beyond the specific implications for prostate cancer, this work establishes a much-needed model for the evaluation, cross-validation, and comparison of multiple cancer profiling studies...
  76. pmc Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
    Qianben Wang
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cell 138:245-56. 2009
    ..Thus, the role of AR in androgen-independent cancer cells is not to direct the androgen-dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgen-independent growth...
  77. ncbi Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era
    Darlene D Lin
    Department of Urology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Urology 65:528-32. 2005
    ..To determine the preoperative and postoperative predictors of a short prostate-specific antigen (PSA) doubling time (PSADT) after radical prostatectomy for patients diagnosed during the PSA era...
  78. ncbi Current thoughts on the role of the androgen receptor and prostate cancer progression
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Adv Anat Pathol 12:265-70. 2005
    ..The need for the design of novel therapeutic analogues is also emphasized...
  79. ncbi Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
    Michael Stanbrough
    Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cancer Res 66:2815-25. 2006
    ..These results indicate that enhanced intracellular conversion of adrenal androgens to testosterone and dihydrotestosterone is a mechanism by which prostate cancer cells adapt to androgen deprivation and suggest new therapeutic targets...
  80. ncbi Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations
    Lakshmi P Kunju
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Am J Clin Pathol 120:737-45. 2003
    ..Most HGPINs show diffuse moderate P504S staining. AAH may show focal P504S staining. We recommend using P504S along with morphologic examination and conventional basal cell markers...
  81. pmc SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines
    Francesca Demichelis
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Nucleic Acids Res 36:2446-56. 2008
    ....
  82. pmc Profiling critical cancer gene mutations in clinical tumor samples
    Laura E MacConaill
    Center for Cancer Genome Discovery, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 4:e7887. 2009
    ..We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting...
  83. ncbi Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system
    Aurelien Descazeaud
    Department of Urology, Henri Mondor Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Prostate 66:1037-43. 2006
    ..Zinc-alpha-2-glycoprotein 1 (ZAG) is a 41-kD secreted protein that is known to stimulate lipid degradation in adipocytes. The aim of this study was to determine how ZAG protein expression is associated with prostate cancer (PCa)...
  84. ncbi Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities
    Scott E Eggener
    J Urol 178:2260-7. 2007
    ....
  85. ncbi Reg IV: a promising marker of hormone refractory metastatic prostate cancer
    Zhennan Gu
    Department of Statistics, Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Cancer Res 11:2237-43. 2005
    ..In comparison, it is not expressed by any normal prostate specimens and only at low levels in approximately 40% of primary tumors. These data support Reg IV as a candidate marker for hormone refractory metastatic prostate cancer...
  86. ncbi Amplification and overexpression of prosaposin in prostate cancer
    Shahriar Koochekpour
    Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Genes Chromosomes Cancer 44:351-64. 2005
    ....
  87. ncbi What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?
    Aurelien Descazeaud
    Department of Urology and Pathology, INSERMEMI03 3, Hopital Henri Mondor, Creteil, France
    Eur Urol 48:911-5. 2005
    ..This survey-based study examines what information urologists are extracting from prostate needle biopsy reports, and what they need for clinical management of prostate cancer (PC) patients...
  88. pmc Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer
    Pamela L Paris
    Department of Urology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Neoplasia 8:1083-9. 2006
    ..Matched primaries and lymph node metastases showed very similar copy number profiles that are distinct from primary tumors that fail to metastasize...
  89. ncbi Tissue microarray sampling strategy for prostate cancer biomarker analysis
    Mark A Rubin
    Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0054, USA
    Am J Surg Pathol 26:312-9. 2002
    ..Conversely, more than 4 cores will not add significant information. This prostate cancer outcomes array should be useful in evaluating other putative prostate cancer biomarkers...
  90. ncbi A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines
    Christopher H Chay
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0946, USA
    Urology 60:760-5. 2002
    ..To identify genes important in prostate cancer metastatic to bone. Bone-specific metastasis is a common feature of prostate cancer and a significant cause of morbidity...
  91. ncbi Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors
    Pamela L Paris
    Comprehensive Cancer Center, University of California at San Francisco, 94115, USA
    Hum Mol Genet 13:1303-13. 2004
    ..Moreover, comparison with an independent set of metastases revealed approximately 40 candidate markers associated with metastatic potential. Copy number aberrations at these loci may define metastatic genotypes...
  92. pmc KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis
    Goutham Narla
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Clin Invest 118:2711-21. 2008
    ..Together, these findings demonstrate that KLF6-SV1 expression levels in PCa tumors at the time of diagnosis can predict the metastatic behavior of the tumor; thus, KLF-SV1 may represent a novel therapeutic target...
  93. ncbi Benign positive margins after radical prostatectomy means a poor prognosis--con
    Mark A Rubin
    Urology 65:221-3. 2005
  94. pmc The role of SPINK1 in ETS rearrangement-negative prostate cancers
    Scott A Tomlins
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 13:519-28. 2008
    ..We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers...
  95. ncbi Prevention of prostate cancer with finasteride
    Mark A Rubin
    N Engl J Med 349:1569-72; author reply 1569-72. 2003
  96. ncbi Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors
    Hassan Chaib
    Department of Urology, The University of Michigan, Ann Arbor 48109, USA
    Genes Chromosomes Cancer 37:306-13. 2003
    ....
  97. pmc Dysregulation of the annexin family protein family is associated with prostate cancer progression
    Wei Xin
    Department of Pathology and the Comprehensive Cancer Center, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Am J Pathol 162:255-61. 2003
    ..Finally, down-regulation of several annexin family members may play a role in the development of the lethal PCa phenotype...
  98. ncbi Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions
    Caleb P Nelson
    Departments of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA
    Urol Oncol 21:213-8. 2003
    ..Tabulated 5-year PSA-free survival outcomes, stratified by these preoperative parameters, provide a basis for preoperative counseling of patients regarding postprostatectomy cancer control expectations...
  99. pmc Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens
    Atreya Dash
    Department of Urology, University of Michigan, Ann Arbor, USA
    Am J Pathol 161:1743-8. 2002
    ....

Research Grants3

  1. Molecular Dissection of Benign Prostatic Hyperplasia
    Mark Rubin; Fiscal Year: 2004
    ..b) Validation of tissue markers using MTOPS samples. Aim 4: Validation of candidate serum biomarkers of symptomatic BPH. a) Serum Microarray Validation using Michigan samples. b) Validation of serum markers using MTOPS samples. ..
  2. "Molecular Signatures of Lethal and Indolent Prostate Cancer"
    Mark Rubin; Fiscal Year: 2007
    ..At the conclusion of this proposal, we expect to have refined and fully validated molecular predictors of PCA death as well as indolent PCA that is appropriate for further clinical development. ..
  3. Towards Understanding Prostate Cancer Heterogeneity
    Mark Rubin; Fiscal Year: 2007
    ..Finally, we will determine if FISH assays (or other in situ tests) can be employed as a prognostic biomarker. ..